Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Franziska Giehren
Observed name:
Giehren, Franziska
Institutions:
University Medical Center Hamburg-Eppendorf,
ERN RARE-LIVER
Observed institutions:
University Medical Center Hamburg-Eppendorf,
ERN RARE-LIVER
OpenAlex ID:
A5016328592
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
2024
·
Joao Gorgulho
, Sven H. Loosen
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
12
PDF
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab
2025
·
Lorenz Kocheise
, Jan Kempski
, et al.
·
Annals of Hepatology
·
6
Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC
2026
·
João Gorgulho
, Ramsha Masood
, et al.
·
Gut
·
3
THU-100 Functional properties of unannotated, small RNA clusters during hepatocarcinogenesis
2025
·
Francesca Pagani
, Franziska Giehren
, et al.
·
Journal of Hepatology
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab
2025
·
Lorenz Kocheise
, Jan Kempski
, et al.
·
Zeitschrift für Gastroenterologie
OS-027-YI Immune checkpoint profiles on circulating extracellular vesicles predict response to immunotherapy in heptaocellular carcinoma
2024
·
Ramsha Masood
, Gustav Buescher
, et al.
·
Journal of Hepatology
Strong efficacy and tolerable safety profile for the combination of atezolizumab and bevacizumab in hepatocellular carcinoma after previous systemic therapy
2023
·
Vincent Jörg
, Martin Schönlein
, et al.
·
Zeitschrift für Gastroenterologie
Show more works
View as search
Works count:
10
Citation count:
21
H-index:
3
I10-index:
1
Year
Topic
Type
